Clinical trial
Janssen - Glucose Regulation/Risp/Olanz
NCT00205738 · Washington University School of Medicine, Other · Completed
Key facts
| NCT number | NCT00205738 |
|---|---|
| Title | Janssen - Glucose Regulation/Risp/Olanz |
| Official title | Glucose Regulation During Risperidone and Olanzapine Treatment |
| Lead sponsor | Washington University School of Medicine, Other |
| Collaborators | Janssen, LP Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Schizophrenia, Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | Risperidone, Olanzapine |
| Enrollment | 120 |
| Start date | Jul 1, 2000 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Sep 20, 2005 |
| Last update posted | Mar 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: